{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T02:38:12Z","timestamp":1780454292395,"version":"3.54.1"},"reference-count":116,"publisher":"Informa UK Limited","issue":"8","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Hematology"],"published-print":{"date-parts":[[2025,8,3]]},"DOI":"10.1080\/17474086.2025.2522956","type":"journal-article","created":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T04:40:58Z","timestamp":1750308058000},"page":"605-617","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Current state-of-the-art of immunotherapy in follicular lymphoma"],"prefix":"10.1080","volume":"18","author":[{"given":"Sean","family":"McKeague","sequence":"first","affiliation":[{"name":"Peter MacCallum Cancer Centre and Royal Melbourne Hospital","place":["Melbourne, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phil","family":"Thompson","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre and Royal Melbourne Hospital","place":["Melbourne, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Seymour","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre and Royal Melbourne Hospital","place":["Melbourne, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,6,25]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2022000361"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17383"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014375"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.7534"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.281421"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314583"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.4648"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00915"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021000"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.7.4051"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2019.01.085"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0155347"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.18251"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2020.02.007"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-217687"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.4766"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-345777"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02365"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1188049"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00591-X"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01622-0"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02986-9"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1384600"},{"key":"e_1_3_4_26_1","unstructured":"Neelapu S. Axicabtagene ciloleucel (axi-cel) in patients with relapsed\/refractory indolent Non-Hodgkin Lymphoma: 4-year follow-up from the phase 2 ZUMA-5 trial. ASH. 2023 [cited 2024 Dec 28]. Available from: https:\/\/ash.confex.com\/ash\/2023\/webprogram\/Paper174914.html"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021243"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.7509"},{"key":"e_1_3_4_29_1","unstructured":"Kite A. Gilead Company. A phase 3 randomized open-label multicenter study evaluating the efficacy of axicabtagene ciloleucel versus standard of care therapy in subjects with relapsed\/refractory follicular lymphoma [internet]. clinicaltrials.Gov. Report No.: nCT05371093. 2024 [cited 2024 Dec 29]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05371093"},{"key":"e_1_3_4_30_1","unstructured":"Thieblemont C. Clinical outcomes of patients with high-risk relapsed\/refractory follicular lymphoma treated with tisagenlecleucel: phase 2 ELARA 4-year update. ASH; 2024 [cited 2024 Dec 29]. Available from: https:\/\/ash.confex.com\/ash\/2024\/webprogram\/Paper201730.html"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.12.068"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021567"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.09.022"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.856"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2023.2289854"},{"key":"e_1_3_4_37_1","unstructured":"Novartis Pharmaceuticals. A randomized open-label multi-center phase III trial comparing tisagenlecleucel to standard of care in adult participants with relapsed or refractory follicular lymphoma (FL) [internet]. Report No.: nCT05888493. [cited 2024 Dec 29]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05888493"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2022.03.013"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011994"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2024.2412869"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1295599"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00931"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00335-7"},{"key":"e_1_3_4_44_1","doi-asserted-by":"crossref","unstructured":"Shadman M. Mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed and\/or refractory follicular lymphoma after \u22652 prior therapies including those with a history of POD24: 4-year follow-up of a pivotal phase II study. ASH; 2024 [cited 2024 Dec 29]. Available from: https:\/\/ash.confex.com\/ash\/2024\/webprogram\/Paper197897.html","DOI":"10.1182\/blood-2024-197897"},{"key":"e_1_3_4_45_1","doi-asserted-by":"crossref","unstructured":"Schuster S. Mosunetuzumab monotherapy continues to demonstrate durable responses in patients with relapsed and\/or refractory follicular lymphoma after \u22652 prior therapies: 3-year follow-up from a pivotal phase II study. ASH; 2023 [cited 2024 Nov 5]. Available from: https:\/\/ash.confex.com\/ash\/2023\/webprogram\/Paper173692.html","DOI":"10.1016\/S2152-2650(24)01563-5"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000971208.36694.eb"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157729"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022348"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025454"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00166-2"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03175"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-148778"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00072-2"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2239"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000967800.55471.36"},{"key":"e_1_3_4_56_1","unstructured":"Genmab A. Phase 3 multicenter randomized open-label trial to evaluate the safety and efficacy of epcoritamab + rituximab and lenalidomide (R2) compared to Chemoimmunotherapy in Previously untreated follicular lymphoma (EPCORETMFL-2) [internet]. clinicaltrials.Gov. Report No.: nCT06191744. 2024 [cited 2024 Dec 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06191744"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-147780"},{"key":"e_1_3_4_58_1","doi-asserted-by":"crossref","unstructured":"Brody J. Fixed-duration epcoritamab in combination with bendamustine + rituximab for first-line treatment of follicular lymphoma: initial results from epcore NHL-2 arm 3. ASH; 2024 [cited 2024 Dec 29]. Available from: https:\/\/ash.confex.com\/ash\/2024\/webprogram\/Paper200369.html","DOI":"10.1182\/blood-2024-200369"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-173677"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-200096"},{"key":"e_1_3_4_61_1","unstructured":"Inc MG. Englumafusp Alfa (CD19\/4-1BBL) combined with Glofitamab Is safe and \u2026 by Franck Morschhauser [Internet]. [cited 2024 Dec 28]. Available from: https:\/\/library.ehaweb.org\/eha\/2024\/eha2024-congress\/422341\/franck.morschhauser.englumafusp.alfa.28cd19.4-1bbl29.combined.with.glofitamab.is.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Ace_id%3D2552%2Aot_id%3D29171%2Amarker%3D5099%2Afeatured%3D18527"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-205544"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-156790"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000919"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01073"},{"key":"e_1_3_4_66_1","doi-asserted-by":"crossref","unstructured":"Falchi L. Subcutaneous (SC) mosunetuzumab (mosun) as first-line therapy for patients (pts) with high tumor-burden follicular lymphoma (FL): first results of a multicenter phase 2 study. ASH; 2023 [cited 2024 Nov 17]. Available from: https:\/\/ash.confex.com\/ash\/2023\/webprogram\/Paper179906.html","DOI":"10.1182\/blood-2023-179906"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-174292"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-193022"},{"key":"e_1_3_4_69_1","doi-asserted-by":"crossref","unstructured":"Morschhauser F. Preliminary findings of a phase Ib\/II trial indicate manageable safety and promising efficacy for mosunetuzumab in combination with lenalidomide (M+len) in Previously untreated (1L) follicular lymphoma (FL). ASH; 2023 [cited 2024 Nov 17]. Available from: https:\/\/ash.confex.com\/ash\/2023\/webprogram\/Paper174432.html","DOI":"10.1182\/blood-2023-174432"},{"key":"e_1_3_4_70_1","unstructured":"The Lymphoma Academic Research Organisation. A phase III randomized open-label International multicenter study evaluating the efficacy and safety of mosunetuzumab plus lenalidomide in comparison to anti-CD20 monoclonal antibody plus chemotherapy in subjects with Previously untreated FLIPI 2\u20135 follicular lymphoma [internet]. clinicaltrials.Gov. Report No.: nCT06284122. 2024 [cited 2024 Nov 17]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06284122"},{"key":"e_1_3_4_71_1","doi-asserted-by":"crossref","unstructured":"Burke J. Fixed-duration subcutaneous mosunetuzumab is active and has a manageable safety profile in patients with Previously untreated low-tumor burden follicular lymphoma: updated results from the phase II morningsun study. ASH; 2024 [cited 2024 Dec 30]. Available from: https:\/\/ash.confex.com\/ash\/2024\/webprogram\/Paper194604.html","DOI":"10.1182\/blood-2024-194604"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.7014"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS7099"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS7096"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614598"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-174668"},{"key":"e_1_3_4_77_1","doi-asserted-by":"crossref","unstructured":"Hou J-Z. Escalating doses of AZD0486 a novel CD19xCD3 T-Cell engager result in high complete remissions with rapid clearance of minimal residual disease in patients with relapsed\/refractory follicular lymphoma. ASH; 2024 [cited 2024 Nov 24]. Available from: https:\/\/ash.confex.com\/ash\/2024\/webprogram\/Paper193589.html","DOI":"10.1182\/blood-2024-193589"},{"key":"e_1_3_4_78_1","unstructured":"Inc MG. Pre-clinical development of AZD5492 a CD8-guided T Cell engager \u2026 by Corinne Cayatte [Internet]. [cited 2024 Nov 17]. Available from: https:\/\/library.ehaweb.org\/eha\/2024\/eha2024-congress\/419500\/corinne.cayatte.pre-clinical.development.of.azd5492.a.cd8-guided.t.cell.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Ace_id%3D2552%2Aot_id%3D29176%2Amarker%3D5101"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-200499"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000967944.12345.32"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13020214"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.9789"},{"issue":"1","key":"e_1_3_4_83_1","first-page":"4055","article-title":"PD-1 blockade with pembrolizumab in relapsed low grade Non-Hodgkin Lymphoma","volume":"130","author":"Ding W","year":"2017","unstructured":"Ding W, Laplant B, Witzig TE, et al. PD-1 blockade with pembrolizumab in relapsed low grade Non-Hodgkin Lymphoma. Blood. 2017;130(Supplement 1):4055.","journal-title":"Blood"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004753"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00539-8"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1807315"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.57_2629"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-178766"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.1169"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30089-4"},{"key":"e_1_3_4_91_1","unstructured":"Sehn L. Tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: results from a phase 3 study (inMIND). ASH; 2024 [cited 2025 Jan 1]. Available from: https:\/\/ash.confex.com\/ash\/2024\/webprogram\/Paper212970.html"},{"key":"e_1_3_4_92_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805104"},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00843"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30441-1"},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.07.007"},{"key":"e_1_3_4_96_1","unstructured":"Weill Medical College of Cornell University. A phase II trial of tazemetostat plus mosunetuzumab in untreated follicular lymphoma [internet]. clinicaltrials.Gov. Report No.: nCT05994235. 2024 [cited 2024 Nov 17]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05994235"},{"key":"e_1_3_4_97_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-179910"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.8853"},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI89756"},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00775"},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS7590"},{"key":"e_1_3_4_102_1","unstructured":"Memorial Sloan Kettering Cancer Center. An open-label multicenter single-arm sequential phase-2 study of mosunetuzumab alone or with Zanubrutinib for the treatment of patients with newly diagnosed follicular lymphoma in need of systemic therapy [internet]. clinicaltrials.Gov. Report No.: nCT05389293. 2024 [cited 2024 Nov 17]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05389293"},{"key":"e_1_3_4_103_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008150"},{"key":"e_1_3_4_104_1","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2022-0173"},{"key":"e_1_3_4_105_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-023-01389-w"},{"key":"e_1_3_4_106_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024526"},{"key":"e_1_3_4_107_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2024000534"},{"key":"e_1_3_4_108_1","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.26342"},{"key":"e_1_3_4_109_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.10.037"},{"key":"e_1_3_4_110_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02786"},{"key":"e_1_3_4_111_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semradonc.2024.10.005"},{"key":"e_1_3_4_112_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02370"},{"key":"e_1_3_4_113_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022432"},{"key":"e_1_3_4_114_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206913"},{"key":"e_1_3_4_115_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023419"},{"key":"e_1_3_4_116_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017726"},{"key":"e_1_3_4_117_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-184883"},{"key":"e_1_3_4_118_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.02.008"}],"container-title":["Expert Review of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17474086.2025.2522956","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T10:24:11Z","timestamp":1754043851000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17474086.2025.2522956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,25]]},"references-count":116,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,3]]}},"alternative-id":["10.1080\/17474086.2025.2522956"],"URL":"https:\/\/doi.org\/10.1080\/17474086.2025.2522956","relation":{},"ISSN":["1747-4086","1747-4094"],"issn-type":[{"value":"1747-4086","type":"print"},{"value":"1747-4094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,25]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-02-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}